Abstract
In early 2012, the Breakthrough Therapy Act was introduced into the US House of Representatives and the Senate. The bills received bipartisan support and were included as an amendment to the Food and Drug Administration Safety and Innovation Act in the Prescription Drug User Fee Act V. On July 9, 2012, the breakthrough therapy designation was signed into law. As of June 13, 2014, a total of 48 products have been designated as breakthrough therapies by the Center for Drug Evaluation and Research, and 4 of those have received FDA new molecular entity approval.
Get full access to this article
View all access options for this article.
References
1.Pub L No. 112-144, § 902 . http://www.gpo.gov/fdsys/pkg/PLAW-122publ144/pdf/PLAW-122publ144.pdf. Accessed May 2, 2013 .
2.Food and Drug Administration . Guidance for industry: expedited programs for serious conditions—drugs and biologics . http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf. Accessed June 30, 2014 .
3.Friends of Cancer Research . Inside health policy—FDA official: breakthrough designation brings high bar, costly investment . http://www.focr.org/breakthrough-therapies. Accessed July 10, 2013 .
4.The Pink Sheet . A regulator’s perspective for 2013: FDA’s temple discusses FDASIA, Caronia, and breakthrough development . http://www.pharmamedtechbi.com/publications/rpm-report/9/2/a-regulators-perspective-for-2013-fdas-temple-discusses-fdasia-emcaroniaem-and-breakthroug. Accessed June 22, 2013 .
5.US Food and Drug Administration . Frequently asked questions: breakthrough therapies .
http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/fdasia/ucm341027.htm. Accessed July 29, 2013 .
6.US Food and Drug Administration . Fact sheet: breakthrough therapies .
http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/fdasia/ucm329491.htm. Accessed August 6, 2013 .
7.Federal Register . Center for Drug Evaluation and Research medical policy council; request for comments . https://www.federalregister.gov/articles/2013/03/18/2013-06142/center-for-drug-evaluation-and-research-medical-policy-council-request-for-comments. Accessed June 30, 2014 .
8.Pharma & MedTech Business Intelligence . What makes a “breakthrough” therapy? Woodcock says more details are coming . http://www.pharmamedtechbi.com/publications/rpm-report/first-take/2013/5/woodcock-on-breakthrough. Accessed September 18, 2013 .
9.Fierce Biotech . Industry voices: breakthrough designation Q&A .
http://www.fiercebiotech.com/story/industry-voices-breakthrough-designation-qa/2013-09-11. Accessed October 21, 2013 .
10.FDA . Genentech approval letter : Gazyva .
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125486Orig1s000ltr.pdf. Accessed December 2, 2013 .
11.FDA . Novartis approval letter : Zykadia .
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205755Orig1s000ltr.pdf. Accessed May 30, 2014 .
12.FDA . Pharmacyclics approval letter : Imbruvica .
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/205552Orig1s000ltr.pdf. Accessed January 14, 2014 .
13.OBR Daily . Will the breakthrough designation shorten development times for oncology agents currently in the pipeline? http://www.obroncology.com/blog/2013/12/will-the-breakthrough-designation-shorten-development-times-for-oncology-agents-currently-in-the-pipeline/. Accessed January 20, 2014 .
14.Fierce Biotech . Ariad Pharma denied FDA’s coveted “breakthrough” stamp for lung cancer drug . http://www.fiercebiotech.com/story/ariad-pharma-denied-fdas-coveted-breakthrough-stamp-lung-cancer-drug/2013-08-09. Accessed October 15, 2013 .